Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
US10668030B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10668030-B2 |
| Application number | US-201715493836-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2017 |
| Priority date | Apr 21, 2016 |
| Publication date | Jun 2, 2020 |
| Grant date | Jun 2, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a substance use disorder of methamphetamine, drug dependence/abuse of methamphetamine, or withdrawal from drug dependence/abuse of methamphetamine in an individual in need thereof comprising administering a compound of formula (I), where the compound of formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine; (R)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine; or pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound of formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine hydrochloride. 3. The method of claim 1 , wherein the (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine; (R)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine; or pharmaceutically acceptable salt thereof is present in a pharmaceutical composition further comprising a pharmaceutically acceptable excipient. 4. The method of claim 3 , wherein the pharmaceutical composition is administered to the individual by inhalation; topically; orally; intravenously as an infusion or injection; or subcutaneously as an infusion, injection, or depot formulation; transdermally; or rectally.
Assignees
Inventors
Classifications
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
- A61K31/137Primary
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10668030B2 cover?
- The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need…
- Who is the assignee on this patent?
- Univ Kentucky Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/137. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).